Sosei Group has been granted a patent for compounds acting as agonists of muscarinic M1 or M1/M4 receptors for treating related diseases. The patent includes the formula for the compounds and their pharmaceutical compositions. GlobalData’s report on Sosei Group gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Sosei Group Corp - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Sosei Group, was a key innovation area identified from patents. Sosei Group's grant share as of January 2024 was 31%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11834407B2) discloses a compound of formula (1) and its various derivatives for potential pharmaceutical applications. The compound, along with its pharmaceutically acceptable salts, is described with specific structural variations, including substitutions on phenyl rings and different moieties. The patent also covers a range of specific compounds falling under the formula, such as ethyl 5-(4-cyano-4-phenylcyclohexyl)-1,5-diazocane-1-carboxylate and 4-{[(1R,3S)-3-(3-methyl-1,2,4-oxadiazol-5-yl)cyclopentyl]amino}-1-(pyridin-2-yl)cyclohexanecarbonitrile, among others.

Furthermore, the patent extends to pharmaceutical compositions containing the disclosed compound or its salts along with suitable excipients. Additionally, a method for treating diseases like Alzheimer's Disease, dementia with Lewy bodies, and schizophrenia is outlined, involving the administration of the compound or its pharmaceutically acceptable salt to patients in need of such treatment. The patent provides a comprehensive framework for the development and potential therapeutic use of the disclosed compound in addressing these specific medical conditions, highlighting its potential significance in the field of pharmaceutical research and drug development.

To know more about GlobalData’s detailed insights on Sosei Group, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies